FDA
-
-
-
-
-
-
-
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
-
-
-
-
-
-
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $15 at Leerink Partners
-
-
-
-
-
-
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird
-
-
-
-
-
-
-
Biohaven receives FDA update on troriluzole drug application
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
-
-
-
-
-
-
-
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

